In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook

Executive Summary

Boston Scientific CEO Jim Tobin, in a series of addresses, defends his company's decision to spend $27.3 billion on Guidant Inc., warts and all. Defying criticism of the deal, Tobin lays out how Boston Scientific management corrected Guidant's problems--and why the new company will thrive.

Related Content

Trends for the New Year: Can Medtech Build on the Success of 2007?
Boston Scientific Shuffles and Sells in Bid to Right Ship
Industry Perspective - The Medtech Industry: A Look Back at 2006
Boston Scientific Takes Conor to Court over DES
Guidant Pioneers Stents' Move North to Carotids
Guidant's Guiding Spirit: An Interview with Beverly Lorell, MD
Guidant: The New Rules of the Device Game
Guidant's Loss of Innocence
Boston Scientific's Buying Spree Continues, This Time in EP
Boston Scientific Goes on a Buying Spree


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts